The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1415
ISSUE1415
April 29, 2013
Regorafenib (Stivarga) for Metastatic Colorectal Cancer and GIST (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Regorafenib (Stivarga) for Metastatic Colorectal Cancer and GIST (online only)
April 29, 2013 (Issue: 1415)
Regorafenib (Stivarga – Bayer), a multikinase inhibitor,
has been approved by the FDA for treatment of
patients with metastatic colorectal cancer previously
treated with multiple other regimens specified in the
labeling. It has also been...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.